Articles tagged with Cancer Patients
A study of 305 patients undergoing radiation treatment found that playing an active role in their treatment decisions improved patient satisfaction. Patients who experienced shared decision making or perceived control over their treatments were more satisfied and reported lower levels of anxiety, depression, and fatigue.
A study by UT Southwestern Medical Center found that popular web information on colorectal cancer screening materials are written beyond the recommended sixth-grade reading level and fail to address key risks and barriers. Only half of the sites discussed colorectal cancer risk in the general population, while only a quarter specifical...
Researchers found a genetic connection between APOBEC family of genes and breast cancer development. The study linked the genes to mutations present in half of all cancer types, supporting their role in cancer-causing processes.
UT Southwestern Medical Center received a $3.24 million grant from the National Cancer Institute to bolster its clinical cancer research and provide patients with access to cancer research trials. The center will expand its offerings of experimental cancer treatments, more than doubling adult participation in clinical trials.
Researchers at Dartmouth's Geisel School of Medicine identified a potential therapeutic target for glioblastoma multiforme, a deadly form of brain cancer. The study found that STK17A protein is induced in response to DNA damage and is correlated with poorer outcomes.
A research team led by Ellis L. Reinherz and Robert I. Haddad will focus on developing new vaccines and immunotherapeutic approaches to improve outcomes for patients with HPV-driven cancers who have relapsed after initial therapy. The grant aims to provide a novel approach to treating this population.
The Bezos family's $20 million donation will support the development of novel cancer immunotherapies for various solid tumor cancers. The gift promises to save lives by expanding the use of immunotherapy to treat a range of deadly cancers.
Researchers at Dartmouth found that disrupting VISTA, a protein preventing overreaction, enhanced the immune system. This discovery may lead to new cancer treatments using the immune system.
The Farrah Fawcett Foundation is supporting a new $1.2 million research team to develop vaccines and immunotherapies for HPV-driven cancers, which currently have few therapeutic options. The team aims to identify tumor targets, activate specific immune cells, and deploy them at the tumor site for selective destruction of cancer.
The Mayo Clinic uses frozen section analysis during breast cancer lumpectomies, sparing patients the need for repeat surgeries in 96% of cases. This technique significantly lowers the 30-day reoperation rate from 13.2% nationally to 3.6% at Mayo.
The SU2C Phillip A. Sharp Innovation in Collaboration Awards aim to foster synergistic and innovative collaborations among SU2C scientists. The inaugural awards will support five grants totaling $950,000, focusing on projects that enhance the SU2C mission to accelerate cancer treatment development.
Researchers at Stanford Medicine have developed a highly sensitive and specific blood test that can accurately identify stage-1 lung cancer patients and detect rare cancer mutations. The CAPP-Seq technique analyzes tumor DNA in the blood to provide non-invasive monitoring of cancer progression and treatment responses.
Patients with HPV+ throat cancer have good prognosis, but tumors elsewhere in the head and neck have no prognostic effect of being HPV+, researchers found. HPV status has significant impact on tumour control, survival, and death from any cause for oropharyngeal cancers.
In mice, obese fathers pass on their weight and gene expression changes to their daughters, increasing the risk of obesity and breast cancer later in life. This study provides evidence for a potential paternal link to cancer risk, challenging traditional research focus on maternal influences.
A clinical trial found that genetic screening can help doctors customize treatments for patients with advanced melanoma, reducing cancer recurrence risk by 63%. The study used ipilimumab therapy and identified biomarker signatures to tailor treatment plans.
A new study found that ovarian cancer patients' disease-free survival rates significantly improved over time, particularly among those with poorer initial prognoses. The research suggests that considering the time elapsed since remission may provide a more accurate prognosis and inform better follow-up care decisions.
Researchers at UPCI discovered that a subset of patients with lobular carcinoma receive less benefit from adjuvant tamoxifen, indicating potential targets for drug therapy. The study suggests a unique signaling pathway regulated by estrogen in lobular carcinoma cells may be exploited in future clinical trials.
Physician Emil J Freireich and scientist Jim Allison have been elected as fellows of the American Association for Cancer Research Academy, known for their contributions to cancer treatment and immunotherapy. Their work has driven significant innovation and progress against cancer, leading to improved survival rates for patients.
A comprehensive review suggests that mammography screening benefits are often exaggerated while harms are understated. The study's findings emphasize the need for individualized approach to breast cancer screening based on clinical factors and personal preferences.
A new study found that certain genetic variants, such as ALDH2 and VCAM1, can predict bladder cancer recurrence in patients. These variants can help identify high-risk patients who require more frequent screenings and aggressive treatment, improving quality of life for all bladder cancer patients.
Researchers estimate that up to 100% of lung cancer patients experience sexual dysfunction, which can persist after treatment. Experts call for open discussions and specialized help from healthcare professionals to address these issues.
Researchers developed a predictive tool that analyzes gene expression changes to predict patient survival. The tool, based on mouse studies, has shown promise in predicting treatment risk for early-stage breast cancer and certain lung cancers.
Scientists have developed a method to freeze testicular tissue in boys undergoing chemotherapy and radiation treatments for cancer, allowing them to preserve fertility. The study found that cancer cells were eliminated during the process of reproducing sperm-producing stem cells, making this option safe for future use.
Researchers discovered that breast cancer tumors can hijack patients' repressive gene regulatory machinery, permanently blocking cancer-killing genes. This allows the cancer to continue growing despite treatment with aromatase inhibitors, which block estrogen synthesis.
A new study identified genetic variants associated with increased risk of bladder cancer recurrence. Inheriting certain DNA sequences may affect a patient's prognosis, allowing physicians to tailor surveillance and treatment plans.
A study at Dana-Farber Cancer Institute found wide variation in oncologists' attitudes towards offering cancer gene testing, with those having high genomic confidence more likely to prescribe the test. The survey revealed that 42% of doctors approved telling patients about uncertain test results, highlighting concerns about delivering ...
Researchers found that people with a rare chromosome abnormality have a 2,700-fold increased risk of a rare childhood leukemia. The fusion of chromosomes 15 and 21 led to chromothripsis, which shattered the chromosome and created an optimised genome for leukaemia.
A groundbreaking study led by TGen has identified a genetic mutation in the SMARCA4 gene as the primary driver of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), a rare and aggressive form of ovarian cancer. This discovery holds promise for developing targeted therapies and improving diagnosis.
New research by USC Norris Comprehensive Cancer Center scientists suggests that elevated CTC counts after chemotherapy indicate a higher risk of death, while reduced CTCs cut the risk in half. This study demonstrates CTCs as an important biomarker for cancer research and treatment.
A new study found that CDK4 inhibitors may promote the development and progression of certain B-cell lymphomas driven by the MYC oncogene. Inhibiting CDK4 leads to genetic instability and genomic alterations associated with cancer growth.
A study by researchers from Huntsman Cancer Institute found that about 6 percent of colorectal cancers are missed during colonoscopies, particularly in patients over 65 and those with a family history of the disease. The cancers may develop rapidly after the procedure or be overlooked due to factors like polyp size or location.
Cologuard detects precancer and cancer with high sensitivity rates, surpassing existing non-invasive tests, offering a user-friendly approach to expand screening effectiveness and curb colorectal cancer rates. The test's accuracy has transformed how we think about colorectal cancer screening.
Researchers at TGen identified the ALK-EML4 gene fusion as the genetic driver of an aggressive type of thyroid cancer. The study's findings suggest that this fusion can be targeted with existing drug crizotinib, offering a new treatment option for patients with radioiodine-resistant aggressive papillary thyroid cancer.
Using big data analytics, researchers can predict the type of breast, lung, or oropharyngeal cancers with high accuracy. This technology may enable doctors to use MRI scans to diagnose more aggressive cancers earlier, leading to faster treatment options and improved patient outcomes.
The Ohio State University has partnered with MedVax Technologies Inc. to develop a cancer peptide vaccine technology for the treatment and prevention of several types of cancer. The partnership aims to bring this groundbreaking technology into clinical trials in the near future, with the goal of improving patient outcomes.
Researchers at UC Davis hope to prove that mobile health technology improves cancer patient care, quality, and reduces costs. The project uses a unique social networking tool to connect patients with their nurse coordinators, family, caregivers, and clinicians.
Research published in Diabetologia found that cancer patients with diabetes have a higher risk of early death due to the combination of diabetes and cancer. Patients treated with insulin had the highest mortality rate, while those with oral hypoglycaemic agents or no treatment showed lower risks
A new national analysis of trends and outcomes reveals that pancreatic cancer surgery remains under-utilized for patients with the deadly disease. Researchers identified factors associated with not receiving surgery in patients with localized pancreatic cancer, including age, race, and location.
A phase I trial found a complete response for 14 months to everolimus and pazopanib in a patient with advanced bladder cancer and rare mTOR genetic mutations. Genomic profiling revealed two alterations that activated the mTOR-mediated cell signaling pathway, rendering the cancer sensitive to the mTOR inhibitor.
Researchers identify two rare mutations in the mTOR gene associated with a complete response to everolimus and pazopanib, leading to improved treatment options for patients. The study provides new insights into personalized medicine and targeted therapies for bladder cancer.
Dr. Robert D. Schreiber receives AACR-CRI Lloyd J. Old Award in Cancer Immunology for his groundbreaking contributions to the field of cancer immunology, including identifying IFNγ as a key cytokine and developing the cancer immunoediting concept.
Researchers have found a potential new treatment for patients with advanced melanoma and kidney cancer. The study used an antibody that targets the tumor-enhancing protein TGFβ, which is involved in cell growth and spread of tumors.
A recent study by Queen's University Belfast highlights the disparities in cancer care for older patients, citing 'undertreatment' and a 'survival gap'. The editorial argues that clinical trials should be without an upper age limit to redress these disparities and improve outcomes.
A new pill called idelalisib shows promise in treating relapsed leukemia and lymphoma patients, with a significant response rate of 72% for CLL patients. However, MCL patients experienced less favorable responses, highlighting the need for further research to improve this therapy.
Dr. Daniel D. Von Hoff, a leading physician and scientist, has made significant advancements in cancer treatment with the development of multiple anticancer agents, including gemcitabine and nab-paclitaxel. His work has improved patient care and survival rates for patients with stage IV pancreatic cancer.
Researchers identified cancer markers and a previously unknown gene role in airways of smokers with lung cancer, suggesting earlier detection and treatment strategies. The study found that normal-appearing tissue near tumors has tumor-associated molecular abnormalities, potentially aiding in diagnosis and treatment.
Researchers found that injecting a virus directly into one melanoma tumor can induce a potent anti-tumor immune response, destroying both infected and non-infected tumors. This combination therapy overcomes the limitations of oncolytic virotherapy and checkpoint blockade.
The Northwestern Medicine Developmental Therapeutics Institute has received a significant $2 million pledge from The Woman's Board of Northwestern Memorial Hospital. This funding will support the launch of the institute, establish its first clinics, and create a fellowship program for physician-scientists specializing in developmental ...
Research suggests that palliative chemotherapy can lead to more invasive medical procedures and a higher risk of death in intensive care units among advanced cancer patients. The findings highlight the need for clearer discussion of the harms and benefits of palliative chemotherapy at the end of life.
Research suggests that terminally ill cancer patients who receive chemotherapy in the last months of life are more likely to undergo intensive medical care and die in an intensive care unit. The study highlights the importance of end-of-life discussions between patients and physicians.
Patients receiving nivolumab survived for an average of 16.8 months, with 62% alive one year after treatment initiation and 43% alive two years later. The drug also shrank tumors in 31% of patients, with some able to remain on the treatment for up to two years.
Dr. Curtis Harris is being recognized for his landmark scientific contributions to the fields of integrative and molecular epidemiology of human cancer and cancer biomarkers. His research has significantly impacted the field of cancer risk assessment and our understanding of the molecular pathogenesis of human cancer.
Researchers at Ohio State University found that inhibiting the enzyme PRMT5 can significantly improve survival in an animal model of GBM. High levels of PRMT5 are associated with aggressive growth and lower overall survival rates in brain cancer patients.
Researchers from the University of Surrey launch eSMART, a programme using mobile phone technology to remotely monitor patients undergoing chemotherapy for breast, bowel and blood cancers. The system assesses symptoms and triggers alerts to doctors or nurses within minutes.
Researchers discovered an unusual genetic mutation in patients with fibrolamellar hepatocellular carcinoma, a rare and aggressive form of liver cancer. The mutated gene, called a chimera, is constantly active and drives the growth of tumor cells.
A recent study found that patients with invasive lobular carcinoma receive less benefit from standard adjuvant therapies compared to those with ductal carcinoma. The research indicates a potential target for drug therapy in future clinical trials, which could lead to more effective treatment options for this subtype of breast cancer.
A new study published in Supportive Care in Cancer has linked handgrip strength to survival rates among patients with advanced-stage cancers. The test measures peak grip strength using a simple device called a dynamometer, providing a direct assessment of body strength and helping doctors determine interventions needed.
In the UK, bladder cancer is the 7th most common cancer and has a high recurrence rate, affecting 28 people daily. Early detection is crucial, as 5-year survival rates can be as high as 80% if treated early.
A new American Cancer Society study reveals that uninsured adolescents and young adults are disproportionately diagnosed with late-stage cancer due to lack of insurance. The research suggests that expanding health coverage, such as the Affordable Care Act, can lead to fewer late-stage diagnoses and ultimately save lives.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that cancer patients seeking information from non-clinician sources were more likely to receive PET scans. The study suggests that exposure to cancer-related information and promotional materials may drive the use of unnecessary imaging procedures.